Cerebrospinal Fluid Proteome in Hydrocephalus
PROLIPHYC
2 other identifiers
interventional
100
1 country
1
Brief Summary
PROLIPHYC is a collaborative prospective study that aims at discovering deep cerebrospinal fluid (CSF) proteome with a new clinically-compatible proteomics strategy, in a cohort of 100 patients suspected of neurodegenerative diseases and/or normal pressure hydrocephalus.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2013
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2013
CompletedFirst Submitted
Initial submission to the registry
June 18, 2013
CompletedFirst Posted
Study publicly available on registry
December 20, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedDecember 15, 2025
November 1, 2020
2.5 years
June 18, 2013
December 5, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
CSF proteome measure
CSF extraction (3 ml)
48 hours
Secondary Outcomes (2)
correlation between CSF proteome and gait analysis
72 hours
correlation between CSF proteome and MRI brain imaging
72 hours
Study Arms (2)
patient
EXPERIMENTALpatient CSF extraction with hydrocephalus
witness
OTHERpatient without hydrocephalus but with peridural catheter for anesthetic. Witness CSF extraction has realized on catheter.
Interventions
Eligibility Criteria
You may qualify if:
- Gait problems, cognitive decline, urinary incontinence and enlarged ventricles on imaging
You may not qualify if:
- Psychiatric disorders
- Lumbar punction contraindication
- RMI contraindication
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital
Toulouse, 31059, France
Related Publications (3)
Guillotin S, Vallet A, Lorthois S, Cestac P, Schmidt E, Delcourt N. Association Between Homocysteine, Frailty and Biomechanical Response of the CNS in NPH-Suspected Patients. J Gerontol A Biol Sci Med Sci. 2022 Jul 5;77(7):1335-1343. doi: 10.1093/gerona/glac074.
PMID: 35325129RESULTVallet A, Del Campo N, Hoogendijk EO, Lokossou A, Baledent O, Czosnyka Z, Balardy L, Payoux P, Swider P, Lorthois S, Schmidt E. Biomechanical response of the CNS is associated with frailty in NPH-suspected patients. J Neurol. 2020 May;267(5):1389-1400. doi: 10.1007/s00415-019-09689-z. Epub 2020 Jan 29.
PMID: 31997040RESULTGuillotin S, Fulzele A, Vallet A, de Peredo AG, Mouton-Barbosa E, Cestac P, Andrieu S, Burlet-Schiltz O, Delcourt N, Schmidt E. Cerebrospinal fluid proteomic profile of frailty: Results from the PROLIPHYC cohort. Aging Cell. 2024 Jul;23(7):e14168. doi: 10.1111/acel.14168. Epub 2024 May 2.
PMID: 38698559RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eric SCHMIDT, MD PhD
University Hospital, Toulouse
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 18, 2013
First Posted
December 20, 2013
Study Start
March 1, 2013
Primary Completion
September 1, 2015
Study Completion
December 1, 2015
Last Updated
December 15, 2025
Record last verified: 2020-11